Does Rallies show Form 4 insider transactions for PODD?

Yes. Rallies tracks PODD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PODD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PODD. It does not provide personalized investment advice.

PODD (Insulet Corporation) Stock Analysis - Insider Trades

Insulet Corporation (PODD) is a publicly traded Healthcare sector company. As of May 21, 2026, PODD trades at $157.13 with a market cap of $10.56B and a P/E ratio of 36.47. PODD moved +1.29% today. Year to date, PODD is -44.77%; over the trailing twelve months it is -52.18%. Its 52-week range spans $145.59 to $354.88. Analyst consensus is buy with an average price target of $262.52. Rallies surfaces PODD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PODD stock inside the company?

Recent PODD insider activity includes MINOGUE MICHAEL R bought 2.03K, McEvoy Ashley bought 4.30K, Frederick Wayne A.I. sold 1.85K, STONESIFER TIMOTHY C. bought 962, and Singh Prem sold 687. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PODD Key Metrics

Key financial metrics for PODD
Metric	Value
Price	$157.13
Market Cap	$10.56B
P/E Ratio	36.47
EPS	$4.30
Dividend Yield	0.00%
52-Week High	$354.88
52-Week Low	$145.59
Volume	0
Avg Volume	0
Revenue (TTM)	$2.90B
Net Income	$302.80M
Gross Margin	71.01%

Recent PODD Insider Trades

MINOGUE MICHAEL R bought 2.03K (~$499.85K) on Feb 25, 2026.
McEvoy Ashley bought 4.30K (~$1.03M) on Feb 20, 2026.
Frederick Wayne A.I. sold 1.85K (~$542.51K) on Dec 15, 2025.
STONESIFER TIMOTHY C. bought 962 (~$299.88K) on Dec 5, 2025.
Singh Prem sold 687 (~$238.73K) on Sep 8, 2025.

Latest PODD News

Insulet Slides After Q1 Beat as Omnipod 5 Class I Recall Overhang Persists — May 6, 2026
Insulet Q1 Net Income $91.1M, Adjusted EPS $1.42 Tops Estimates — May 6, 2026
Insulet rises as FDA updates Omnipod 5 Class I recall details ahead of earnings — May 1, 2026
Insulet jumps as traders buy ahead of May 6 earnings after 52-week low — Apr 30, 2026
Insulet drops 4% as FDA recall database highlights Omnipod 5 Pod action — Apr 29, 2026

PODD Analyst Consensus

23 analysts cover PODD: 0 strong buy, 18 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $262.52.

Common questions about PODD

Who is trading PODD stock inside the company?: Recent PODD insider activity includes MINOGUE MICHAEL R bought 2.03K, McEvoy Ashley bought 4.30K, Frederick Wayne A.I. sold 1.85K, STONESIFER TIMOTHY C. bought 962, and Singh Prem sold 687. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PODD?: Yes. Rallies tracks PODD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PODD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PODD. It does not provide personalized investment advice.